Back Education
Education
Back Resources
Resources
Back About Us
About Us
an icon of a microscope, indicating research and science
Our Research Initiatives

Long Covid: One Disease or Several?

September 15, 2023

A recent review article published in Nature provides the most comprehensive compilation of research on long Covid to date, discussing what is currently known about its symptoms, prevalence, biomarkers, and disease mechanisms. 

The most common symptoms of Long Covid appear to be weakness, malaise, fatigue, impaired concentration, and breathlessness. Researchers agree that at least 10% of people who’ve had COVID-19 develop Long Covid. Estimates vary based on how researchers define Long Covid, the time frame post-infection, and the population under study. Some report closer to 50% and others less than 10%; the search for a definitive diagnostic test for Long Covid is ongoing. Biomarkers include low serum cortisol, chemokine CCL-11, autoantibodies shared with known autoimmune diseases, and certain intestinal microbiota. 

It remains unclear how protective COVID-19 vaccination is against Long Covid. Some studies suggest that breakthrough infections are just as likely to result in Long Covid as infections in unvaccinated individuals, and vaccination may not reduce the severity of symptoms (1) (2) (3). Others find vaccination to be protective or even beneficial for treating those who already have Long Covid symptoms (4) (5) (6) (7).

The authors argue that because Long Covid has such broad multi-systemic symptoms, it likely has a broad range of causes and will likely be classified into separate illnesses in the future. They support this argument with the lack of a single unifying mechanism. 

Research supports microclots, viral reservoirs, organ damage, autoimmunity, viral reactivation, and dysbiosis as potential causes for Long Covid symptoms. It is unlikely that all of these mechanisms play a role for every Long Covid patient, but some patients are affected by each. Future studies, diagnostic tests, and treatments will likely target specific sub-groups within the larger Long Covid population.





Sources

  1. Article Sources and Footnotes

    1. Altmann, D. M., Whettlock, E. M., Liu, S., Arachchillage, D. J., & Boyton, R. J. (2023). The immunology of long COVID. Nature reviews. Immunology, 23(10), 618–634. https://doi.org/10.1038/s41577-023-00904-7

    2. Antonelli, M., Penfold, R. S., Merino, J., Sudre, C. H., Molteni, E., Berry, S., Canas, L. S., Graham, M. S., Klaser, K., Modat, M., Murray, B., Kerfoot, E., Chen, L., Deng, J., Österdahl, M. F., Cheetham, N. J., Drew, D. A., Nguyen, L. H., Pujol, J. C., Hu, C., … Steves, C. J. (2022). Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. The Lancet. Infectious diseases, 22(1), 43–55. https://doi.org/10.1016/S1473-3099(21)00460-6

    3. Ayoubkhani, D., Bermingham, C., Pouwels, K. B., Glickman, M., Nafilyan, V., Zaccardi, F., Khunti, K., Alwan, N. A., & Walker, A. S. (2022). Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. BMJ (Clinical research ed.), 377, e069676. https://doi.org/10.1136/bmj-2021-069676

    4. Carneiro, V. L., Littlefield, K. M., Watson, R., Palmer, B. E., & Lozupone, C. (2024). Inflammation-associated gut microbiome in postacute sequelae of SARS-CoV-2 points towards new therapeutic targets. Gut, 73(2), 376–378. https://doi.org/10.1136/gutjnl-2022-328757

    5. Gold, J. E., Okyay, R. A., Licht, W. E., & Hurley, D. J. (2021). Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation. Pathogens (Basel, Switzerland), 10(6), 763. https://doi.org/10.3390/pathogens10060763

    6. Hastie, C. E., Lowe, D. J., McAuley, A., Winter, A. J., Mills, N. L., Black, C., Scott, J. T., O’Donnell, C. A., Blane, D. N., Browne, S., Ibbotson, T. R., & Pell, J. P. (2022). Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study. Nature communications, 13(1), 5663. https://doi.org/10.1038/s41467-022-33415-5

    7. Kell, D. B., Laubscher, G. J., & Pretorius, E. (2022). A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications. The Biochemical journal, 479(4), 537–559. https://doi.org/10.1042/BCJ20220016

    8. Michelen, M., Manoharan, L., Elkheir, N., Cheng, V., Dagens, A., Hastie, C., O’Hara, M., Suett, J., Dahmash, D., Bugaeva, P., Rigby, I., Munblit, D., Harriss, E., Burls, A., Foote, C., Scott, J., Carson, G., Olliaro, P., Sigfrid, L., & Stavropoulou, C. (2021). Characterising long COVID: a living systematic review. BMJ global health, 6(9), e005427. https://doi.org/10.1136/bmjgh-2021-005427

    9. Pisanic, N., Antar, A. A. R., Kruczynski, K., Rivera, M. G., Dhakal, S., Spicer, K., Randad, P. R., Pekosz, A., Klein, S. L., Betenbaugh, M. J., Detrick, B., Clarke, W., Thomas, D. L., Manabe, Y. C., & Heaney, C. D. (2022). Methodological approaches to optimize multiplex oral fluid SARS-CoV-2 IgG assay performance and correlation with serologic and neutralizing antibody responses. medRxiv : the preprint server for health sciences, 2022.12.22.22283858. https://doi.org/10.1101/2022.12.22.22283858

    10. Son, K., Jamil, R., Chowdhury, A., Mukherjee, M., Venegas, C., Miyasaki, K., Zhang, K., Patel, Z., Salter, B., Yuen, A. C. Y., Lau, K. S., Cowbrough, B., Radford, K., Huang, C., Kjarsgaard, M., Dvorkin-Gheva, A., Smith, J., Li, Q. Z., Waserman, S., Ryerson, C. J., … Mukherjee, M. (2023). Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long COVID symptoms. The European respiratory journal, 61(1), 2200970. https://doi.org/10.1183/13993003.00970-2022

    11. Stein, S. R., Ramelli, S. C., Grazioli, A., Chung, J. Y., Singh, M., Yinda, C. K., Winkler, C. W., Sun, J., Dickey, J. M., Ylaya, K., Ko, S. H., Platt, A. P., Burbelo, P. D., Quezado, M., Pittaluga, S., Purcell, M., Munster, V. J., Belinky, F., Ramos-Benitez, M. J., Boritz, E. A., … Chertow, D. S. (2022). SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature, 612(7941), 758–763. https://doi.org/10.1038/s41586-022-05542-y

    12. Taquet, M., Dercon, Q., & Harrison, P. J. (2022). Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections. Brain, behavior, and immunity, 103, 154–162. https://doi.org/10.1016/j.bbi.2022.04.013

    13. Thompson, E. J., Williams, D. M., Walker, A. J., Mitchell, R. E., Niedzwiedz, C. L., Yang, T. C., Huggins, C. F., Kwong, A. S. F., Silverwood, R. J., Di Gessa, G., Bowyer, R. C. E., Northstone, K., Hou, B., Green, M. J., Dodgeon, B., Doores, K. J., Duncan, E. L., Williams, F. M. K., OpenSAFELY Collaborative, Steptoe, A., … Steves, C. J. (2022). Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nature communications, 13(1), 3528. https://doi.org/10.1038/s41467-022-30836-0

    14. Tsuchida, T., Hirose, M., Inoue, Y., Kunishima, H., Otsubo, T., & Matsuda, T. (2022). Relationship between changes in symptoms and antibody titers after a single vaccination in patients with Long COVID. Journal of medical virology, 94(7), 3416–3420. https://doi.org/10.1002/jmv.27689

    15. Willyard C. (2022). Could tiny blood clots cause long COVID’s puzzling symptoms?. Nature, 608(7924), 662–664. https://doi.org/10.1038/d41586-022-02286-7

    16. Zhou, Y., Han, T., Chen, J., Hou, C., Hua, L., He, S., Guo, Y., Zhang, S., Wang, Y., Yuan, J., Zhao, C., Zhang, J., Jia, Q., Zuo, X., Li, J., Wang, L., Cao, Q., & Jia, E. (2020). Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19. Clinical and translational science, 13(6), 1077–1086. https://doi.org/10.1111/cts.12805